Search company, investor...

Predict your next investment

Corporate Venture
pfizer.com/partners/venture-investments

Investments

192

Portfolio Exits

44

Funds

1

Partners & Customers

1

About Pfizer Venture Investments

Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, Strategy, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline.

Headquarters Location

235 East 42nd Street

New York, New York, 10017,

United States

Want to inform investors similar to Pfizer Venture Investments about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Pfizer Venture Investments

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Pfizer Venture Investments in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Research containing Pfizer Venture Investments

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Pfizer Venture Investments in 1 CB Insights research brief, most recently on Jan 19, 2021.

Latest Pfizer Venture Investments News

Nimbus Therapeutics Secures $210M

Sep 19, 2023

Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The round was co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture, with participation from another new investor that is a U.S.-based life sciences-focused fund as well as existing investors Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Pfizer Venture Investments Investments

192 Investments

Pfizer Venture Investments has made 192 investments. Their latest investment was in Nimbus Therapeutics as part of their Series G on September 9, 2023.

CBI Logo

Pfizer Venture Investments Investments Activity

investments chart

Pfizer Venture Investments Portfolio Exits

44 Portfolio Exits

Pfizer Venture Investments has 44 portfolio exits. Their latest portfolio exit was Pyxis Oncology on October 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/8/2021

IPO

$99M

Public

9

7/20/2021

Acq - Fin

$99M

1

6/15/2021

Acquired

$99M

1

5/28/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/27/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/8/2021

7/20/2021

6/15/2021

5/28/2021

5/27/2021

Exit

IPO

Acq - Fin

Acquired

Acquired

Acq - Pending

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

9

1

1

10

10

Pfizer Venture Investments Acquisitions

1 Acquisition

Pfizer Venture Investments acquired 1 company. Their latest acquisition was Saama Technologies on October 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/20/2021

Debt

$99M

$79.25M

Acq - Fin

14

Date

10/20/2021

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$79.25M

Note

Acq - Fin

Sources

14

Pfizer Venture Investments Fund History

1 Fund History

Pfizer Venture Investments has 1 fund, including Pfizer Venture Investments.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/6/2018

Pfizer Venture Investments

$600M

2

Closing Date

6/6/2018

Fund

Pfizer Venture Investments

Fund Type

Status

Amount

$600M

Sources

2

Pfizer Venture Investments Partners & Customers

1 Partners and customers

Pfizer Venture Investments has 1 strategic partners and customers. Pfizer Venture Investments recently partnered with Nodality on August 8, 2012.

Date

Type

Business Partner

Country

News Snippet

Sources

8/9/2012

Partner

United States

South San Francisco, California, August 9, 2012. Nodality :: Company :: News and Resources :: Press Releases / Company News Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease.

Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting .

2

Date

8/9/2012

Type

Partner

Business Partner

Country

United States

News Snippet

South San Francisco, California, August 9, 2012. Nodality :: Company :: News and Resources :: Press Releases / Company News Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease.

Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting .

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.